Quick Answer
Quince Therapeutics, Inc. reported Long Term Debt of $14.32 million for the year ending 2024.
- Quince Therapeutics, Inc. showed an increase of +6.6% in Long Term Debt from 2023 to 2024.
- This data is from Quince Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $13.52 million | Q2 2024: $13.83 million | Q3 2024: $14.90 million | Q4 2024: $14.32 million | Q1 2025: $15.27 million | Q2 2025: $16.99 million | Q3 2025: $0.00.
- Historical annual values: Fiscal year 2024: $14.32 million | Fiscal year 2023: $13.43 million | Fiscal year 2022: $0.00.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: